
    
      This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center
      non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of
      KSI-301 5 mg in participants with visual impairment due to treatment-na√Øve macular edema
      secondary to RVO (either branch and central type).

      The primary endpoint will be assessed at Week 24; additional secondary endpoints for efficacy
      will be assessed at Week 24 and Week 48.
    
  